- Shopping Bag ( 0 items )
From The CriticsReviewer: John A. Robinson, MD (Loyola University Stritch School of Medicine)
Description: This is a duo-authored monograph written at the technical level by two PhDs in the field that discusses the current status and attempts to predict the future of the rapidly changing field of antibody therapeutics.
Purpose: It is comforting to know that scientific ingenuity is alive and well and especially manifest in the rapidly developing new methods on how to create and manufacture antibodies for diagnosis and therapy.
Audience: This book will be a helpful source for the interested neophyte, immunoengineer, or immunologist who wants to keep current in a very complex subfield of immunobiology.
Features: This book could have benefited from the addition of some clinical perspective. A striking example of this deficiency is the rather benign neglect of the extensively documented cytokine storm that occurs early during OKT3 therapy, CMV infection/reactivation, and the probable increased incidence of posttransplant lymphoproliferative disease with the use and overuse of this anti T-cell monoclonal. There is at least one serious typographical error designating the wrong CD for OKT3 in a table, but, on the other hand, several very helpful color illustrations that greatly facilitated the understanding of humanized antibodies, etc. have been included. Although the publisher states that this series of books is published 60 to 90 days after acceptance of the manuscripts, it is still clear that timeliness of the manuscripts are still a problem. Most of the discussion in this book is relevant to clinical trials completed at least two or more years before publication.
Assessment: On the whole, I recommend this book as a way to introduce oneself to the wonderful world of gene and protein engineering or to develop a perspective of a very difficult but potentially therapeutic revolution in clinical medicine.